



Unit 6-10, Zeus Building
Rutherford Avenue
Harwell, Didcot OX11 0DF
United Kingdom

Issue Class: Ordinary Shares

- (1) This information statement applies to the Taxable Year of Barinthus Biotherapeutics plc (the "Fund") beginning on **January 1, 2023 and ending on December 31, 2023.**
- (2) The amounts below represent income per share per day for investors holding interests in the Ordinary Shares during the Fund's taxable year specified in paragraph 1.

Amount Per Share Per Day

Ordinary Earnings:	USD	NONE
Net Capital Gain:	USD	NONE

An investor's share of ordinary earnings and net capital gain can be computed as follows:

(Amount Per Share Per Day X Number of shares X Number of days each share was held in the tax year)

- (3) The amount of cash and fair market value of other property distributed or deemed distributed by the Fund to the Shareholder during the Fund's taxable year specified in paragraph 1:

(Please note that this amount **excludes** amounts you may have received upon redemption of your interests in the fund):

Cash/Fair market value of other property: **NONE**

- (4) The Fund will permit the shareholder to inspect and copy the Fund's permanent books of account, records and such other documents as may be maintained by the Fund to establish that the Fund's ordinary earnings and net capital gain, as provided in Section 1293(e) of the Internal Revenue Code of 1986, as amended, are computed in accordance with U.S. income tax principles and to verify these amounts and this shareholder's pro rata shares thereof.

By: *Gemma Brown*

Title: CFO

Barinthus Biotherapeutics plc

Date: July 8, 2024